文献速递慢性肾脏病肾小球疾病

局灶节段性肾小球硬化患者慢性肾脏病进展的分层复合终点

A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis.
PubMed 文献 · Clin J Am Soc Nephrol · 2026-01-26

该研究将新开发的分层复合终点(HCE)应用于DAPA-CKD试验中115例FSGS患者,评估达格列净对CKD进展的作用。结果显示HCE的win-odds为1.52(95%CI 1.01, 2.28),优于主要复合终点和eGFR斜率,且统计功效更高。提示HCE是评估FSGS治疗效应的敏感高效指标。

要点

  • HCE在FSGS患者中显示达格列净获益,win-odds 1.52(95%CI 1.01, 2.28)。
  • 主要复合终点和eGFR斜率的95%CI均跨越无效线。
  • 相同样本量下HCE的统计功效高于传统终点。

核心结论

  • 整合已确立CKD终点与eGFR斜率的分层复合终点,可敏感且高效地评估FSGS患者的治疗效应。

研究设计与样本

  • 对DAPA-CKD随机双盲安慰剂对照试验中115例FSGS患者的事后分析,比较达格列净对主要复合终点、eGFR斜率和CKD进展HCE的效应。

主要发现

  • 达格列净对主要复合终点的风险比为0.45(95%CI 0.13, 1.49),总eGFR斜率差异为0.9 mL/min/1.73m2(95%CI -0.6, 2.3),95%CI均跨越1或0。
  • CKD进展HCE的win-odds为1.52(95%CI 1.01, 2.28),提示达格列净获益且95%CI未跨越1。
  • 在给定样本量下,CKD进展HCE的统计功效高于主要复合终点或eGFR斜率。

临床怎么用

  • 在FSGS等罕见肾病临床试验中,可考虑采用CKD进展HCE作为更高效的终点,但需在前瞻性试验中验证。

局限性

  • 该分析为DAPA-CKD试验的事后亚组分析,样本量较小(115例),HCE尚未在前瞻性临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We recently developed and validated a hierarchical composite endpoint (HCE) for chronic kidney disease (CKD) progression combining time-to-event kidney outcomes with the rate of estimated glomerular filtration rate (eGFR) decline (eGFR slope). The CKD progression HCE is an informative endpoint for clinical trials in rare kidney diseases, such as focal segmental glomerulosclerosis (FSGS), where event-driven trials are often infeasible. METHODS: We applied a HCE for CKD progression to the subset of patients with FSGS from the DAPA-CKD trial, a randomized double-blind, placebo-controlled clinical trial, to assess the effects of the sodium glucose co-transporter 2 inhibitor dapagliflozin on CKD progression in 4304 participants. We compared treatment effects for the primary composite endpoint (sustained 50% eGFR decline, kidney failure, or death due to kidney or cardiovascular causes), eGFR slope, and CKD progression HCE. We also compared statistical power for these outcomes using a bootstrap sampling procedure to evaluate the impact on trial efficiency. RESULTS: Overall, 115 participants were included (mean age, 54 years; 68% male; median urinary albumin-to-creatinine ratio, 1283 mg/g; mean eGFR, 42 mL/min/1.73m2). The effect of dapagliflozin on the primary composite endpoint (hazard ratio 0.45 [95% confidence interval [CI]: 0.13, 1.49]) and total eGFR slope (0.9 mL/min/1.73m2 (95%CI: -0.6, 2.3) were consistent with the overall trial results but the 95% CI crossed unity. The win-odds for the CKD progression HCE suggested benefits for dapagliflozin and the 95%CI did not cross unity (win-odds: 1.52 [95%CI: 1.01, 2.28]). Power calculations suggested that for a given sample size, statistical power was higher for the CKD progression HCE compared with the primary composite endpoint or eGFR slope. CONCLUSION: Our findings suggest that a CKD progression HCE, which integrates established CKD endpoints and eGFR slope, provides a sensitive and efficient measure to assess treatment effects in patients with FSGS. Validation of the HCE in prospective clinical trials will support its implementation.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Heerspink HJL, Little DJ, Gasparyan SB, et al. A Hierarchical Composite Endpoint for Chronic Kidney Disease Progression in Patients with Focal Segmental Glomerulosclerosis. Clin J Am Soc Nephrol. 2026. PMID: 41587099. doi:10.2215/CJN.0000000994

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。